利伐沙班上市没？

Rivaroxaban tablets are an oral, bioavailable factor Xa inhibitor that can selectively block the active site of factor Xa and does not require cofactors, such as antithrombin III, so it can exert activity and activate factor X into factor Xa through endogenous and exogenous pathways, playing an important role in medical measurement reactions. Today we will find out whether rivaroxaban is on the market?

In terms of taking: 1. Rivaroxaban 10mg can be taken with food or alone. Rivaroxaban 15 mg or 20 mg tablets should be taken with food.

2. To prevent venous thrombosis in adult patients undergoing elective hip or knee replacement surgery, the recommended dose is oral rivaroxaban 10 mg, once daily. If the wound has stopped bleeding, the first dose of medication should be between 6 and 10 hours after surgery.

3. For patients undergoing major hip surgery, the recommended treatment course is 35 days. For patients undergoing major knee surgery, the recommended course of treatment is 12 days. If a missed dose occurs, the patient should take rivaroxaban immediately and continue taking the dose once daily the next day.

4. Treat DVT and reduce the risk of acute DVT recurrence and PE. The recommended dose for the initial treatment of acute DVT is 15 mg twice a day for the first three weeks. After that, the dose for maintenance treatment and reducing the risk of DVT recurrence and PE is 20 mg once a day.

Rivaroxaban is a small molecule oral anticoagulant jointly developed by Bayer and Johnson & Johnson, with the trade name Xarelto. It obtained marketing approval in Canada and the European Union on September 15 and October 1, 2008 respectively. Domestically, rivaroxaban tablets were approved for marketing by the State Food and Drug Administration in March 2009, and were successfully included in the 2009 National Medical Insurance List in the same year. On July 1, 2011, the FDA approved the drug for the prevention of deep vein thrombosis in patients undergoing knee or hip replacement surgery.

Rivaroxaban is also a drug used to prevent and treat venous thrombosis. Clinically, it is mainly used to prevent the formation of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients after hip and knee replacement surgery. It can also be used to prevent stroke and non-central nervous system embolism in patients with non-valvular atrial fibrillation, and reduce the risk of recurrence of coronary syndrome.

The above is the content of rivaroxaban on the market, I hope it can help you!